NCT06726785 Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment
| NCT ID | NCT06726785 |
| Status | Recruiting |
| Phase | — |
| Sponsor | HBC Immunology Inc |
| Condition | Restless Leg Syndrome (RLS) |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2025-07-01 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to observe changes in dopaminergic genes expression in peripheral tissue upon prolonged dopamine agonist treatment on patients with Restless Legs Syndrome (RLS). Similar studies in Parkinson's disease have shown changes in alpha-synuclein expression, which might offer insights into the dopaminergic gene regulation seen in RLS. The dopamine agonist drugs to be included in this study are: Pramipexole (Mirapex), Ropinirole (Requip), Rotigotine (Neupro), Apomorphine (Apokyn), Bromocriptine (Parlodel). Specifically, the study will collect nasal swabs of participants partitioned into two groups, those who have not used a dopamine agonist or been on a dopamine agonist for less than 1 month compared to those who have been on the medication for 6 or more months. This research could provide insight into changes in dopaminergic gene expression associated with Augmentation Syndrome (AS) which occurs after long term dopamine agonist treatment in RLS patients.
Eligibility Criteria
Inclusion Criteria: * Able to provide Informed Consent * Clinical diagnosis of Restless Legs Syndrome (RLS) * On-going Treatment with a dopamine agonist Exclusion Criteria: \* Use of any medication that might affect nasal epithelial cell collection with a nasal swab
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06726785 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Restless Leg Syndrome (RLS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06726785 currently recruiting?
Yes, NCT06726785 is actively recruiting participants. Contact the research team at bomi.framroze@hbcimmunology.com for enrollment information.
Where is the NCT06726785 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT06726785 clinical trial?
NCT06726785 is sponsored by HBC Immunology Inc. The trial plans to enroll 50 participants.